Malaria evolution in South Asia: knowledge for control and elimination

The study of malaria parasites on the Indian subcontinent should help us understand unexpected disease outbreaks and unpredictable disease presentations from Plasmodium falciparum and Plasmodium vivax infections. The Malaria Evolution in South Asia (MESA) research program is one of ten International Centers of Excellence for Malaria Research (ICEMR) sponsored by the US National Institutes of Health. In this second of two reviews, we describe why population structures of Plasmodia in India will be characterized and how we will determine their consequences on disease presentation, outcome and patterns. Specific projects will determine if genetic diversity, possibly driven by parasites with higher genetic plasticity, plays a role in changing epidemiology, pathogenesis, vector competence of parasite populations and whether innate human genetic traits protect Indians from malaria today. Deep local clinical knowledge of malaria in India will be supplemented by basic scientists who bring new research tools. Such tools will include whole genome sequencing and analysis methods; in vitro assays to measure genome plasticity, RBC cytoadhesion, invasion, and deformability; mosquito infectivity assays to evaluate changing parasite-vector compatibilities; and host genetics to understand protective traits in Indian populations. The MESA-ICEMR study sites span diagonally across India and include a mixture of very urban and rural hospitals, each with very different disease patterns and patient populations. Research partnerships include government-associated research institutes, private medical schools, city and state government hospitals, and hospitals with industry ties. Between 2012 and 2017, in addition to developing clinical research and basic science infrastructure at new clinical sites, our training workshops will engage new scientists and clinicians throughout South Asia in the malaria research field.

From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors

The blockade of Akt activation through the inhibition of 3-phosphoinositide-dependent kinase-1 (PDK-1) represents a major signaling mechanism whereby celecoxib mediates apoptosis. Celecoxib, however, is a weak PDK-1 inhibitor (IC(50), 48 microM), requiring at least 30 microM to exhibit discernable effects on the growth of tumor cells in vitro. Here, we report the structure-based optimization of celecoxib to develop PDK-1 inhibitors with greater potency in enzyme inhibition and growth inhibition. Kinetics of PDK-1 inhibition by celecoxib with respect to ATP suggest that celecoxib derivatives inhibit PDK-1 by competing with ATP for binding, a mechanism reminiscent to that of many kinase inhibitors. Structure-activity analysis together with molecular modeling was used to generate compounds that were tested for their potency in inhibiting PDK-1 kinase activity and in inducing apoptosis in PC-3 prostate cancer cells. Docking of potent compounds into the ATP-binding site of PDK-1 was performed for lead optimization, leading to two compounds, OSU-03012 and OSU-03013, with IC(50) values in PDK-1 inhibition and apoptosis induction in the low microM range. Exposure of PC-3 cells to these agents led to Akt dephosphorylation and inhibition of p70 S6 kinase activity. Moreover, overexpression of constitutively active forms of PDK-1 and Akt partially protected OSU-03012-induced apoptosis. Screening in a panel of 60 cell lines and more extensive testing in PC-3 cells indicated that the mean concentration for total growth inhibition was approximately 3 microM for both agents. Considering the conserved role of PDK-1/Akt signaling in promoting tumorigenesis, these celecoxib analogs are of translational relevance for cancer prevention and therapy.

Investigation by NMR spectroscopy of the interaction between synthetic soluble (-)-dopa melanin and drugs

In order to understand the molecular interactions of drugs with melanin, synthetic soluble (-)-dopa-melanin was prepared in deuterium buffer. The spectra of various drug moieties with the pigment at 30 degrees C were studied employing the line width measurements obtained with a pulse NMR (AF270) instrument. As compared to drug effects in fresh melanins (48 h), the aged melanins (greater than or equal to 168 h) gave consistent spectral measurements, even in dilute solutions of pigment. NMR signals of aromatic and N-methyl protons of drugs were relatively easy to quantify and, in the presence of melanin, line broadening of various drug moieties occurred. The line widths of the N-methyl groups of acetylcholine (3.02 ppm), the N-methyl group of atropine (2.52 ppm), N-isopropyl of isoprenaline bitartrate (1.14 ppm) and N-ter-butyl of timolol maleate (1.22 ppm) in the presence of the pigment were increased. Line widths associated with acetate, bitartrate, maleate or tropic acid, however, were not altered by the melanin. This indicates the specificity of the interaction between drug moieties and the site(s) of melanin. Based on the line width measurements of N-methyl protons of ephedrine, two dissociation constants were obtained (Kd1 2.08 mM and Kd2 greater than 20 mM). The constants for atropine melanin complex were Kd1 0.79 mM and Kd2 greater than 6 mM. Furthermore, based on N-methyl resonances, it appears that atropine and ephedrine compete for at least one common interacting site of the melanin polymer.